Goubet Anne-Gaëlle, Daillère Romain, Routy Bertrand, Derosa Lisa, M Roberti Paula, Zitvogel Laurence
U1015 INSERM, université Paris-11, Saclay, Institut Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France.
U1015 INSERM, université Paris-11, Saclay, Institut Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France.
C R Biol. 2018 May-Jun;341(5):284-289. doi: 10.1016/j.crvi.2018.03.004. Epub 2018 Apr 7.
Accumulating evidence points to the impact of the gut microbiota in regulating various chronic inflammatory disorders such as cancers. The intestinal microbiome is not only influencing the spontaneous course of colon malignancies but also acts at distant sterile sites of neoplasia, mostly playing a detrimental role. By providing microbial-associated molecular patterns and potentially antigens sharing molecular mimicry with tumor antigens, our commensals modulate the local and the systemic immune tonus, eventually influencing tumor microenvironment. Complicating this algorithm, therapeutic interventions alter the delicate balance between the epithelium, the microbial community, and the intestinal immunity, governing the final clinical outcome. This seminar focused on the impact of the intestinal composition on the immunomodulatory and therapeutic activities of distinct compounds (alkylating agents, platinum salts and immunotherapies) used in oncology. This research opens up "the era of anticancer probiotics" aimed at restoring gut eubiosis for a better clinical outcome in cancer patients.
越来越多的证据表明肠道微生物群在调节各种慢性炎症性疾病（如癌症）中发挥着作用。肠道微生物组不仅影响结肠恶性肿瘤的自然病程，还作用于远处的肿瘤无菌部位，大多发挥有害作用。通过提供微生物相关分子模式以及可能与肿瘤抗原存在分子模拟的抗原，我们的共生菌调节局部和全身免疫张力，最终影响肿瘤微环境。使这一机制更为复杂的是，治疗干预会改变上皮细胞、微生物群落和肠道免疫之间的微妙平衡，从而决定最终的临床结果。本次研讨会聚焦于肠道组成对肿瘤学中使用的不同化合物（烷化剂、铂盐和免疫疗法）的免疫调节和治疗活性的影响。这项研究开启了“抗癌益生菌时代”，旨在恢复肠道微生态平衡，以改善癌症患者的临床结局。
